2025 · 2nd Quarter (Apr 1 - June 30)

MERCK & CO. INC.

Filed by THE NICKLES GROUP, LLC.

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 17, 2025
Income: $50,000.00
Expenses: Not reported
Registrant: THE NICKLES GROUP, LLC
Client: MERCK & CO. INC.
Filing UUID: 59d8304b-130c-4607-aff2-98e91c27cc07
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 946/S. 1862, ORPHAN Cures Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. H.R.1, One Big Beautiful Bill Act, as it relates to drug pricing and pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing.

Literal federal measure citations: H.R. 946, S. 1862, H.R. 1492, H.R.1

TAX · Taxation/Internal Revenue Code

H.R. 1, One Big Beautiful Bill Act, as it relates to corporate taxes.

Literal federal measure citations: H.R. 1

TRD · Trade (domestic/foreign)

Issues related to tariffs.

HCR · Health Issues

Issues related to pharmacy benefit management reforms. Issues related to vaccine policy. Issues related to supply chain and domestic manufacturing capacity.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.